NOX 4.17% 6.9¢ noxopharm limited

Ann: Major Survival Benefit in Prostate Cancer Patients Announced, page-20

  1. 926 Posts.
    lightbulb Created with Sketch. 596

    While the individual cohort medians aren't separated out, the dose escalation is clearly making a difference. The median OS of the 1,200mg cohort is tracking somewhere around 22 months I'd think.

    Two points -
    - our median OS is vastly better than on 177 Lu-PSMA 617 alone
    - the OS per cohort is extending with each dose escalation of idronoxil

    Fantastic

    Last edited by PickEm: 09/02/21
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.